Our lab’s recent investigation revealed unique, p53-dependent upregulation of TLR3 by irinotecan compared to treatment with 5-FU, oxaliplatin, or cisplatin at equitoxic doses in colorectal cancer cells, suggesting a novel irinotecan-specific impact on the TME [13]. The gene discussed is TP53; the disease is colorectal cancer.